| abstract |
Novel and neurodegenerative disorders having an antagonistic action against novel oxa- or thia-aliphatic bridge-bonded quinoxaline-2,3-diones and their pharmaceutically acceptable salts of the following general formula (I) Their use with the nature of treatment.n n n n n n n n (In the formula, A 1 is a lower alkylidene or a group represented by the formula> CH-A 4 -R 4 ( La), A 2 is a lower alkylidene or a group represented by the formula> CH-A 4 -R4 (Ia ),> C = O (Ob ) Or? CH (OH) -A 5 -R 4 (Ic), A 3 is an oxy, optionally oxidized thio or> C = O (Ib) group, A 4 is lower alkylene, A 5 is lower alkylene or Direct bond, n is 0 or 1, R 1 and R 2 are each independently hydrogen, unsubstituted or lower alkyl- and / or lower alkanoyl-substituted amino, nitro, lower alkanoyl, free or etherified or esterified Hydroxy, free or esterified or aminated carboxy, cyano, optionally halogenated lower alkyl or halogen, R 3 is hydrogen or hydroxy, and R 4 is hydrogen, cyano, free or esterified or aminated carboxy, free Or esterified phosphono or 5-tetrazolyl.) |